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Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a cigarette smoke (CS)-driven inflammatory airway disease with an
increasing global prevalence. Currently there is no effective medication to stop the relentless progression of this disease. It
has recently been shown that an activator of the P2X7/inflammasome pathway, ATP, and the resultant products (IL-1b/IL-
18) are increased in COPD patients. The aim of this study was to determine whether activation of the P2X7/caspase 1
pathway has a functional role in CS-induced airway inflammation. Mice were exposed to CS twice a day to induce COPD-like
inflammation and the role of the P2X7 receptor was investigated. We have demonstrated that CS-induced neutrophilia in a
pre-clinical model is temporally associated with markers of inflammasome activation, (increased caspase 1 activity and
release of IL-1b/IL-18) in the lungs. A selective P2X7 receptor antagonist and mice genetically modified so that the P2X7
receptors were non-functional attenuated caspase 1 activation, IL-1b release and airway neutrophilia. Furthermore, we
demonstrated that the role of this pathway was not restricted to early stages of disease development by showing increased
caspase 1 activation in lungs from a more chronic exposure to CS and from patients with COPD. This translational data
suggests the P2X7/Inflammasome pathway plays an ongoing role in disease pathogenesis. These results advocate the
critical role of the P2X7/caspase 1 axis in CS-induced inflammation, highlighting this as a possible therapeutic target in
combating COPD.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is an inflam-
matory disease of the airways, associated primarily with cigarette
smoke (CS) exposure, and characterised by a progressive and
irreversible decline in lung function caused by airflow obstruction,
destruction of parenchyma and emphysema [1,2]. It is one of the
few leading global causes of death that is still increasing in
prevalenceandispredictedtobe the thirdleadingcauseofmortality
by the year 2020 [3].Studies examiningthe lungsofCOPDpatients
have demonstrated the infiltration of immune cells including CD8
+
T-cells, neutrophils and macrophages and as such inflammatory
cells have been implicated in the pathogenesis of COPD [4]. This
hypothesis, however, is yet to be tested because there are currently
no medications that will reduce the airway inflammation. Indeed,
even high systemic doses of glucocortoid treatment have limited
effects [5]. Therefore there is an urgent need to develop effective
anti-inflammatory drugs for patients suffering from COPD. To do
this we would argue that it is essential to determine the mechanisms
by which exposure to CS drives the airway inflammation.
Recently there has been growing evidence to implicate the
NLRP3 inflammasome and its products in the inflammation
observed in COPD patients. The NLRP3 inflammasome is a
multi-meric protein complex important in stimulating caspase-1
activation and subsequently the release of the mature form of the
inflammatory cytokines IL-1b and IL-18. Elevated IL-1b levels are
found in induced sputum and BAL fluid from COPD patients [6,7].
Adult mice over-expressing IL-1b in lung epithelium display a
COPD-like phenotypeconsisting of lung inflammation, emphysema
and airway fibrosis [8]. Elevated IL-18 levels have also been found
in COPD patients and mouse models [9,10]. Furthermore, IL-18
knockout mice show significantly decreased inflammation and
emphysema compared to wild-type mice following CS exposure
[11]; whereas mice over-expressing IL-18 in the lung display a
COPD-like phenotype [12]. Therefore, a mechanism attenuating
both cytokines may provide a substantial clinical benefit.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24097The NLRP3 inflammasome can be activated a number of ways;
one of which is through ATP acting on the P2X7 receptor
[13,14,15,16]. Extracellular concentrations of ATP are maintained
at low physiological concentrations by ectonucleotidases, but these
concentrations increase under conditions such as infection or
inflammation. This increase can be due to either greater release of
ATP from cells such as epithelial or leukocytes, and/or down-
regulation of ectonucleotidases [17,18]. Recently, increases in
ATP levels have been reported in in vitro/in vivo models of COPD
[19,20] and in clinical samples [21,22]. This increase in ATP levels
has been suggested to play a role in the chemotaxis and activation
of inflammatory cells, such as neutrophils, through P2Y receptors
[22,23]. We suggest, however, that as the expression of the P2X7
receptor is increased in disease tissues/cells [22,24] an alternative
hypothesis could be that the ATP is acting on the P2X7 receptor
leading to NLRP3 inflammasome and caspase 1 activation, which
in turn cleaves the pro-form of IL-1b and IL-18 allowing them to
be released. Indeed, Churg et al have recently shown that caspase 1
inhibition to attenuate a smoke driven airway inflammation [25].
These cytokines then play a central role in the inflammation
observed in COPD. Our hypothesis is that modulation of this
P2X7/inflammasome axis would attenuate CS-induced inflam-
mation.
Using in vitro and in vivo pre-clinical modelling systems we show a
temporal correlation between markers of the P2X7/inflamma-
some pathway activation and airway inflammation. We demon-
strate that modulation of this pathway, using either a selective
P2X7 inhibitor or P2X7 knockout mice, attenuates the airway
inflammation in this in vivo model. This pathway, however, was not
involved in the IL-1b release observed after the activation of
innate host defence mechanisms triggered by an endotoxin insult.
Finally, using samples from patients with COPD, we show our pre-
clinical results are translational in that caspase 1 activity levels are
higher in lung tissue from COPD patients and smokers compared
to non-smoking donors.
Methods
Male C57BL/6 mice were obtained from Harlan UK Limited.
P2X7 receptor knockout (KO) mice (backcrossed at least 7 times)
were provided by Professor Jean Kanellopoulos (Universite ´ Paris-
Sud, France), originally these mice were produced in Professor
Gabel’s lab. For full details of how they were developed see Solle et
al, 2001 [26]. Parallel wild type controls were bred in-house. The
experiments were performed in accordance with the UK Home
Office guidelines for animal welfare based on the Animals
(Scientific Procedures) act 1986 under a project licence (PPL
70/6681).
Development and characterisation of CS driven model of
airway inflammation
A whole body cigarette smoke exposure system consisting of a
time-set pinch valve (C Lee Machining, Horsham, UK), exposure
chambers(Teague Enterprises,CA,USA),extractionunit(Grainger
Industrial Supply, USA) and TSP Sampling Unit (Teague
Enterprises, CA, USA). Animals were exposed to either room air
or cigarette smoke using 3R4F cigarettes (Cigarette filter removed,
Tobacco Health Research Institute, University of Kentucky,
Lexington, KY). CS is generated using a negative pressure system
(flow-rate set at 1500 ml/min through the system) and timer pinch-
valve to pump in smoke for pre-determined times based on the
concentration of smoke required within the chambers. Room air is
continuously pumped into the chamber for the remaining period
between puffs. The duration of exposure periods was 50 minutes
followed by a 10 minute venting period at the end where the flow is
increased to maximum. Exposures for each group will take place in
one of the Teague chambers (136L) chambers. A fan is placed at the
bottom of the chamber on the left side where the smoke enters the
chamber to ensure that the smoke is well dispersed throughout the
chamber. Total suspended particulate (TSP) levels are assessed for
each chamber at 15 minute intervals (15, 30, 45 minutes - 1 min
sampling period) in order to validate the consistency of the smoke
concentration within the chambers.
Dose response. Mice were exposed to either room air
(1500 ml/minute) or CS (250, 500 or 750 ml/min in a total of
1500 ml/minute) using 3R4F cigarettes (Tobacco Health Research
Institute) for 50 minutes, twice daily, for three consecutive days.
BAL fluid white cell counts (neutrophils, monocytes/macrophages,
eosinophils and lymphocytes) were determined as previously
described [27].
Time course. Temporal changes in airway inflammation
following CS exposure (500 ml/min) were assessed (samples taken
2, 6, 24, 48, 72, 96 and 168 hours after last challenge).
Figure 1. Characterisation of CS and LPS challenge models.
Mice were challenged with air or CS (1 hour, twice a day, for 3 days) and
lungs lavaged 24 hours after final exposure; neutrophil numbers are
presented in panel A. Mice were challenged with aerosolised saline or
LPS (30 minutes) and lungs lavaged 6 hours after exposure; neutrophil
numbers are presented in panel B. The arrows indicate the challenge
dose we chose to continue our studies. Data represent mean 6
s.e.mean, n=6. * indicates statistically significant difference from air/
saline control group (One-way ANOVA with a Dunn’s post test).
doi:10.1371/journal.pone.0024097.g001
P2X7 Receptor and Airway Inflammation
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assessed using an assay from Enzo Life Sciences UK Limited.
mRNA expression levels were measured using either Super array
Custom RT
2 Profiler PCR arrays from Tebu-Bio or real-time
PCR using standard techniques and validated primers/probes
[27]. Cytokines were assessed using either ultrasensitive plates
from Mesoscale Discovery or standard ELISA from R&D systems.
Development and characterisation of lipopolysaccharide
(LPS) driven model of airway inflammation
Parallel experiments were performed using a stimulus of the
normal innate defence system, LPS [27]. Briefly, LPS challenging
was performed using a Perspex chamber (60062406350 mm) and
a System 22 nebuliser (Medic-Aid Ltd., Pagham, Sussex) driven by
a high-flow-rate compressor (Medic-Aid Ltd., Pagham, Sussex).
Animals were exposed to either aerosolised LPS (Escherichia coli,
serotype 0111:B4, Sigma-Aldrich Ltd. Poole, UK) or endotoxin
free saline (Fresenius Kabi, Warrington, UK) blown into the
Perspex chamber for a 30 minute challenge period.
Role of P2X7 receptor in CS/LPS driven airway
inflammation
Wild-type and P2X7
2/2 mice were exposed to the previously
established CS or LPS exposure protocol. Twenty-four or six hours
after the final exposure airway inflammation was assessed.
Effect of P2X7 receptor antagonist on CS-induced airway
inflammation
Mice were treated with vehicle (0.5% methyl cellulose and 0.2%
tween80 in distilled H2O, 10 ml/kg, p.o.) or A-438079, 1 hour
priortothefirstexposureand 1 hourafterthesecondexposureeach
day. Animals were then exposed to either room air or CS as above.
Airwayinflammationwas assessed 24 hoursafter the final exposure.
Effect of P2X7 receptor antagonist on LPS induced airway
inflammation
Mice were treated with vehicle or A 438079 orally, 1 hour prior
to challenge. Airway inflammation was assessed 6 hours after the
LPS challenge.
Characterisation of a more chronic CS model
Male mice were exposed to room air or cigarette-smoke
(500 ml/min), twice daily. Airway inflammation was determined
24 hours after 3, 7, 10, 14, 17, 21, 24 or 28 days of challenging.
Role of P2X7 receptor in the more chronic CS driven
airway inflammation
Wild-type and P2X7
2/2 mice were exposed to room air or CS
twice a day for 28 days. Twenty-four after the final exposure
airway inflammation was assessed.
Figure 2. Temporal characterisation of P2X7 – NLRP3 inflammasome associated end points in the CS driven murine model. Mice
were challenged with air or CS (1 hour, twice a day, for 3 days) and samples collected at various times after the last challenge. (A) Caspase 1 activity in
the lung tissue (B) IL-1b levels in the BALF (C) IL-18 levels in the BALF (D) numbers of neutrophils in the BALF. Data represent mean 6 s.e.mean, n=6.
* indicates statistically significant difference from time matched control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g002
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Human lung tissue samples were obtained from a transplant
programme. Informed written consent was obtained for the use of
human tissues for research. Ethical approval for the study was
obtained from the Royal Brompton and Harefield ethics
committee (09/H0708/72).
Compounds and materials
AZ 11645373 was kindly provided by Astra Zeneca Pharmaceu-
ticals. A 438079 was synthesized by Peakdale Molecular. All other
agentswerepurchasedfromSigma-Aldrich unless otherwisedescribed.
Data analysis
Data is expressed as mean 6 s.e.m of n observations. Statistical
significance was determined using either Student’s t-test or One-
way ANOVA followed by an appropriate post-hoc test. A P value
,0.05 was taken as significant and all treatments were compared
with the appropriate control group.
Results
Development and characterisation of CS driven model of
airway inflammation
Exposure to CS resulted in a dose-related increase in white blood
cells in the airway lumen; predominantly neutrophils (Figure 1A).
The 500 ml/min dose of CS was selected as a sub-maximal
stimulant dose and used throughout this project.
Temporal characterisation of the effects of CS exposure
revealed that there appeared to be a correlation between the
increase in caspase 1 activity, IL-1b/IL-18 release and airway
neutrophilia (Figure 2). Caspase 1 activity in the cell free BALF
was not altered (data not shown). Further analysis showed that CS
challenge did not greatly alter lung tissue levels of IL-1b, IL-18,
pro-caspase 1 and P2X7 mRNA (Text S1; Figure S1).
Development and characterisation of LPS driven model
of airway inflammation
Exposure to endotoxin, a trigger of the innate host defence
mechanism, resulted in a dose-related increase in white blood cells
in the airway lumen; again the profile of cell type increased was
predominantly neutrophilia (Figure 1). The 1 mg/ml dose of LPS
was selected as a sub-maximal stimulant dose and used throughout
this project.
Temporal characterisation of the effects of LPS exposure
revealed that there appeared to be a correlation between the
increase in IL-1b/IL-18 release and airway neutrophilia (Figure 3),
however unlike the CS model there was no increase in caspase 1
activity. Caspase 1 activity in the cell free BALF was not altered
(data not shown). Further analysis showed that mRNA levels of pro-
caspase 1 and IL-1b increased dramatically in the lung tissue after
Figure 3. Temporal characterisation of P2X7 – NLRP3 inflammasome associated end points in the LPS driven murine model. Mice
were challenged with vehicle (endotoxin free sterile saline for 30 minutes) or LPS (1 mg/ml) and samples collected at various times after the last
challenge (A) Caspase 1 activity in the lung tissue (B) IL-1b levels in the BALF (C) IL-18 levels in the BALF (D) numbers of neutrophils in the BALF. Data
represent mean 6 s.e.mean, n=6. * indicates statistically significant difference from time matched control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g003
P2X7 Receptor and Airway Inflammation
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24097Figure 4. Role of the P2X7 – NLRP3 inflammasome axis in the CS driven murine model. Wild type or P2X7 knockout mice were challenged
with air or CS and samples collected 24 hours after the last challenge. (A) Caspase 1 activity in the lung tissue (B) IL-1b levels in the BALF (C) IL-1a
levels in the BALF (D) IL-6 levels in the BALF (E) KC levels in the BALF (F) numbers of neutrophils in the BALF. Data represent mean 6 s.e.mean, n=8.
# indicates statistically significant difference from air challenge control group. * indicates statistically significant difference from CS challenged
control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g004
P2X7 Receptor and Airway Inflammation
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mRNA levels were either not altered or decreased (Figure S2).
Role of P2X7 receptor in CS driven airway inflammation
Having established there was temporal correlative data to
suggest a role for the P2X7-inflammasome pathway in CS driven
inflammation, we further investigated its role by comparing wild-
type and P2X7
2/2 mice. As can be seen in Figure 4, CS exposure
failed to increase caspase 1 activity, IL-1b and airway neutrophilia
in P2X7
2/2 mice. This is strong evidence for a role of the P2X7-
inflammasome axis in CS-induced airway neutrophilia. Interest-
ingly, levels of IL-1a and IL-6 were also attenuated in the
knockout mice, whereas KC levels were not altered (Figure 4).
Role of P2X7 receptor in LPS driven airway inflammation
Figure 3 indicated that in the endotoxin driven inflammation
there was not a role for the P2X7-inflammasome axis. To
investigate this further wild-type and P2X7
2/2 mice were
challenged with LPS. As expected P2X7
2/2 mice did not have
altered levels of the inflammasome linked IL-1b, or indeed IL-1a
(Figure 5). Interestingly, we did observe a statistical significant
increase in BAL KC levels and neutrophilia (Figure 5).
Establishing optimum P2X7 inhibitor
To confirm the data with the P2X7
2/2 mice we wanted to
parallel the study using a selective small molecular weight receptor
inhibitor. Prior to doing this we needed to establish an appropriate
tool to use in our murine model. To do this we first selected
appropriate human and mouse cells to develop a P2X7-
inflammasome driven in vitro assay. We detected P2X7 receptor
and pro-caspase 1 expression at the mRNA and protein level in
human (THP-1) and mouse (J774) monocytes/macrophages (Text
S1; Figure S3). Using these cell types we established sub-maximal
concentrations of ATPcS (P2X7 agonist) or LPS that induced IL-
1b release (data not shown). Combination of these two stimuli
resulted in enhanced release of inflammasome linked cytokines,
IL-1b and IL-18, but not other cytokines such as TNFa and
IL-6 (data not shown). Using these systems we determine the
impact of 2 structurally distinct P2X7 inhibitors. The combina-
tion of ATPcS and LPS leads to enhanced IL-1b release (Text
S1; Figure S4). Treatment with AZ 11645373 attenuated the
enhanced release of IL-1b in human cells, suggesting successful
blockade of the human P2X7 receptors, but not murine cells (Text
S1; Figure S4). Conversely, A 438079 failed to have an impact in
the human cell assay but did block the enhanced release of IL-1b
from murine cells (Text S1; Figure S4). A 438079 did not alter
levels of TNFa or IL-6 (data not shown). We did not detect any IL-
1a release in either of the cell systems (data not shown).
Effect of P2X7 receptor antagonist on CS/LPS-induced
airway inflammation
Having selected an appropriate tool to block murine P2X7
receptors we profiled it in the CS driven model. Consistent with the
P2X7
2/2 mice, the compound caused a dose related inhibition in
airway neutrophilia (Figure 6A). Lymphomononuclear cell num-
bers: Air/Vehicle278.065.9; CS/Vehicle2119.4611.7; CS/com-
Figure 5. Role of the P2X7 – NLRP3 inflammasome axis in the LPS driven murine model. Wild type or P2X7 knockout mice were
challenged with saline or LPS and samples collected 6 hours after the last challenge. (A) IL-1b levels in the BALF (B) IL-1a levels in the BALF (C)K C
levels in the BALF (D) numbers of neutrophils in the BALF. Data represent mean 6 s.e.mean, n=8. # indicates statistically significant difference from
air challenge control group. * indicates statistically significant difference from CS challenged control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g005
P2X7 Receptor and Airway Inflammation
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cell 10
3/ml.
In the LPS driven model, unlike in the P2X7
2/2 mice, the
compound had no impact on neutrophil levels (Figure 6B).
Lymphomononuclear cell numbers: Saline/Vehicle269.365.2;
LPS/Vehicle238.966.4; LPS/compound (1000 mg/kg)234.16
3.6; LPS/P2X7 2/22 34.167.3 cell 10
3/ml.
Characterisation of a more chronic CS model
The data so far strongly suggested that the P2X7-inflammasome
axis is central to the inflammation induced after CS exposure. To
determine if this axis is important in ongoing inflammation, we
measured markers of the pathway in a more chronic model.
Temporally correlated with the increase in neutrophils and
macrophages observed (Figure 7), we measured an increase in
caspase 1 activity and IL-1b levels. This suggests that the P2X7-
inflammasome axis is not only central to the induction of CS-
induced inflammation but also in the ongoing inflammation.
Role of P2X7 receptor in a more chronic CS driven airway
inflammation
To further investigated the P2X7-inflammasome axis in the
more chronic model we compared the inflammation in wild-type
and P2X7
2/2 mice after 28 days of CS exposure. As can be seen
Figure 6. Role of the P2X7 – NLRP3 inflammasome axis in the CS or LPS driven murine models. (A) Wild type or P2X7 2/2 mice were
challenged with air or CS and received vehicle (0.5% methyl cellulose and 0.2% tween80 in distilled water, 10 ml/kg, orally) or A 438079 twice a day
and one hour prior to the cull. Numbers of neutrophils in the airway lumen was measured twenty-four hours after the final challenge. (B) Wild type or
P2X7 2/2 mice were challenged with saline or LPS and received vehicle or A 438079 1 hour prior to challenge. Numbers of neutrophils in the airway
lumen was measured six hours after the challenge. Data represent mean 6 s.e.mean, n=8. # indicates statistically significant difference from air/
saline challenge control group. * indicates statistically significant difference from CS/LPS challenged control group (One-way ANOVA with a Dunn’s
post test).
doi:10.1371/journal.pone.0024097.g006
P2X7 Receptor and Airway Inflammation
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2/2 mice had significantly reduced caspase 1
activity, BAL IL-1b, neutrophils and lymphocytes. Macrophages
numbers were also reduced (data not shown).
Expression of P2X7-inflammasome axis in human tissue
To determine if our observations in the pre-clinical models
translated into the human disease, we measured caspase 1 activity
in lung tissue from non-smoking donors, smoking donors and
emphysema patients (details of which are listed in Table 1).
Although the sample numbers and patient information are limited,
it can be clearly seen that, like in our pre-clinical models, caspase 1
activity is increased in diseased tissue (Figure 9).
Discussion
COPD is a progressive condition associated with exposure to
CS and is currently reported to be the fourth leading cause of
death worldwide and is predicted to rise to the third [3].
Furthermore, COPD-related costs outstrip those of other respira-
tory diseases such as asthma and as yet there are currently no
pharmacological therapies to combat the pathogenesis and
relentless progression of this disease [5]. Understanding the
mechanisms driving the chronic inflammation seen in patients
with the disease would undoubtedly aid the development of
effective medication. In the inflammatory milieu present in the
lungs of smoke-exposed mice, and human patients with COPD,
are increased levels of cytokines linked to the activation of the
NLRP3 inflammasome i.e. IL-1b and IL-18 [6,7,8,9,10,28]. There
is some evidence to suggest that these cytokines are central to the
inflammation seen in models of COPD [11,29]. Recently it has
been shown that levels of an activator of the NLRP3 inflamma-
some, ATP, are increased in pre-clinical smoke-exposure models
[23,24]. Additionally, increased ATP levels in the lungs of patients
with COPD have been shown to be associated with a decline in
lung function and an increase in inflammatory cellular burden
[21]. We suggest that exposure to CS leads to the release of
endogenous danger signals (e.g. ATP) which activates the NLRP3
inflammasome via the P2X7 purinergic receptor [13] and thus
causes the maturation and subsequent release of IL-1b and IL-18.
We hypothesise that blockade of the P2X7 – NLRP3 inflamma-
some pathway will attenuate the inflammation present in CS-
induced airway inflammation. Through the use of in vitro and in
vivo pre-clinical modelling systems we showed a temporal
correlation between markers of the P2X7/inflammasome pathway
activation and airway inflammation. Furthermore, we demon-
strate that modulation of this pathway, using either a selective
P2X7 inhibitor or P2X7 knockout mice, attenuates the airway
inflammation in this disease model. This data is consistent with
data recently published by Lucattelli et al [24]. This pathway,
however, was not involved in a similar inflammatory response (i.e.
IL-1b release) observed after the normal innate defence mecha-
nism is triggered by an endotoxin insult suggesting that this
Figure 7. Temporal characterisation of P2X7 – NLRP3 inflammasome associated end points in the sub-chronic CS driven murine
model. Mice were challenged with air or CS (1 hour, twice a day, for 3–28 days) and lungs lavaged 24 hours after final exposure. A) Caspase 1 activity
in the lung tissue (B) IL-1b levels in the BALF (C) numbers of neutrophils in the BALF (D) numbers of macrophages in the BALF. Data represent mean
6 s.e.mean, n=6. * indicates statistically significant difference from time matched control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g007
P2X7 Receptor and Airway Inflammation
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samples collected from patients with COPD, we demonstrate that
markers of inflammasome activation are evident in tissue from
diseased patients with COPD.
Exposure to CS, whether it be acute (induction of the
inflammation) or more chronic (up to 28 days), resulted in an
increase in caspase 1 activity and release of NALP-3 inflamma-
some linked cytokine IL-1b. A similar increase in caspase 1 activity
was observed in lung tissue from patients with COPD so severe/
chronic that they required a lung transplant which suggests that
the pre-clinical model reflects the clinical disease and that the role
of caspase 1 is not restricted to the induction of the inflammation
but is chronically elevated. We postulate that the increase in
activity was not due to an increased amount of caspase 1 because
we did not observe an increase in mRNA expression. On caveat is
that the increase in caspase activity observed in the human lung
samples may not be through activation of the P2X7 receptor as
other things (like uric acid or reactive oxygen species) than can
activate NLRP3. Further assessment of the CS models revealed no
change in IL-1b mRNA levels which is intriguing because we did
measure an increase in this cytokine at the protein level. As the
mechanism of action of glucocorticoids is generally thought to be
blockade of transcription/translation of inflammatory cytokines,
this could be one reason why the inflammation observed in COPD
patients is resistant to glucocortoid treatment. If the inflammation
is driven via a mechanism which does not rely on transcription/
translation it could explain the limited impact of a steroid
treatment.
Further evidence for a central role of the P2X7 – NLRP3
inflammasome pathway in CS-induced neutrophilia came from
the studies we performed with either mice missing functional
P2X7 receptors or a small molecular weight inhibitor. The fact
that we obtained very similar data using both mechanisms of
blocking the P2X7 receptor makes the results more compelling. It
was interesting to note that cytokines not thought to be linked to
the inflammasome/caspase 1 were also reduced after blockade of
the P2X7 receptor. We suggest that the reduction in IL-1a and IL-
6 could be a function of blocking the neutrophilia, rather than a
direct effect on the production/release of the cytokines themselves.
Indeed in the cell based systems cytokines such as IL-6 and TNFa
were not affected by the P2X7 inhibitor. We could not detect any
IL-1a release in our human and mouse cell based systems which,
although possibly different to that reported by others [30], would
Figure 8. Role of the P2X7 – NLRP3 inflammasome axis in the sub-chronic CS driven murine model. Wild type or P2X7 knockout mice
were challenged with air or CS twice a day for 28 days and samples collected 24 hours after the last challenge. (A) Caspase 1 activity in the lung tissue
(B) IL-1b levels in the BALF (C) numbers of neutrophils in the BALF (D) numbers of lymphocytes in the BALF. Data represent mean 6 s.e.mean, n=5–
8. # indicates statistically significant difference from air challenge control group. * indicates statistically significant difference from CS challenged
control group (Mann-Whitney test).
doi:10.1371/journal.pone.0024097.g008
Table 1. Details on the donor/recipient.
Disease Group Age (years) Sex (M/F)
Non-Smoking Donor 27–72 3/9
Smoking Donor 22–62 7/3
Emphysema 49–69 17/8
doi:10.1371/journal.pone.0024097.t001
P2X7 Receptor and Airway Inflammation
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mechanisms which govern IL-1b/IL-18 release. IL-1a release
has been suggested to be controlled by IL-1b, thus it could be that
the inhibition of IL-1b release accounts for the reduction we
observed in IL-1a [31]. The observation that the levels of KC
were not affected by blockade of the P2X7–inflammasome axis is
worthy of note. It would suggest that the CS-induced production/
release of KC is via another mechanism, its source being cells
present in the lung, rather than the neutrophils being recruited.
To establish an appropriate pharmacological P2X7 tool to use
in the murine models we used human and murine cell based
assays. We selected the cell type based on the expression of targets
of interest i.e. the P2X7 receptor and caspase 1 and from the
literature [26,32]. We found that human THP-1 cells and murine
equivalent J774 cells expressed both targets at the mRNA and
protein level, whereas the epithelial cell lines (A549 and LA4) did
not which is consistent to that reported by other groups [31]. This
would suggest that the inflammasome-linked cytokines in the
airways are more likely to be produced by macrophages/
monocytes rather than epithelial cells. When we stimulated the
THP-1/J774 cells with both LPS and ATP the level of IL-1b
release was greater than the sum of the stimuli separately. Using
these modelling systems we demonstrated that the P2X7 receptor
was central to this enhanced release of IL-1b; this has been
demonstrated by many other groups [16,26,32,33,34]. Of interest
to us was that AZ 11645373 failed to impact on the murine cells,
whereas A 438079 only impacted on the murine system, even
though it is reported to act on the human receptor [35]. Despite
the apparent lack of activity in the human cell system, we were
able to use A 438079 as a tool in our murine models.
Interestingly although IL-1b (and IL-1a) levels after LPS
challenge was not altered in the P2X7 2/2 mice, we did observe
an increase in airway KC and neutrophilia. The fact that we did
not parallel this increase with the P2X7 inhibitor may indicate that
the phenomenon is related to either the genetic manipulation or
long term/complete blockade of this receptor.
In conclusion these results advocate the critical role of the
P2X7/inflammasome axis in cigarette smoke induced inflamma-
tion. What is more the data suggests that the pathway has an
ongoing role in the pathogenesis of COPD and highlights it as
possible therapeutic targets in combating this deadly disease.
Supporting Information
Figure S1 Temporal characterisation of P2X7 – NLRP3
inflammasome associated end points in the CS driven
murine model. Mice were challenged with air or CS (1 hour,
twice a day, for 3 days) and samples collected at various times after
the last challenge. (A) IL-1b mRNAlevelsin the lung tissue (B) IL-18
mRNA levels in the lung tissue (C) caspase 1 mRNA levels in the
lung tissue (D) P2X7 mRNA levels in the lung tissue. Data represent
mean 6 s.e.mean, n=6. * indicates statistically significant difference
from time matched control group (Mann-Whitney test).
(TIF)
Figure S2 Temporal characterisation of P2X7 – NLRP3
inflammasome associated end points in the LPS driven
murine model. Mice were challenged with saline or LPS
(30 minutes) and samples collected at various times after the last
challenge.(A)IL-1b mRNAlevelsinthelung tissue(B)IL-18 mRNA
levels in the lung tissue (C) caspase 1 mRNA levels in the lung tissue
(D) P2X7 mRNA levels in the lung tissue. Data represent mean 6
s.e.mean, n=6. * indicates statistically significant difference from
time matched control group (Mann-Whitney test).
(TIF)
Figure S3 Caspase 1 and P2X7 mRNA levels in a range
of human and mouse cell type. Cells were collected after
standard culture conditions, mRNA extracted and RT-PCR
performed to establish mRNA expression levels of caspase 1 and
P2X7. Caspase 1 mRNA levels in human and murine cells are
shown in A and C, respectively. P2X7 mRNA levels in human and
murine cells are shown in B and D, respectively. Data represent
mean 6 s.e.mean, n=3–6.
(TIF)
Figure S4 Determining the effectiveness of P2X7 recep-
tor antagonist using human and mouse monocytes.
Cultured cells were exposed to either sub-maximal concentration
of ATPcs (1 mM) or LPS (0.1 mg/ml) or a combination of the two.
Cells were pre-treated with vehicle or one of the inhibitors; IL-1b
levels were measured by ELISA. (A) Effect of AZ 11645373 in
THP-1 cells (B) Effect of AZ 11645373 in J774 cells (C) Effect of A
438079 in THP-1 cells (D) Effect of A 438079 in J774 cells. Data
represent mean 6 s.e.mean, 3 experimental runs each with n=2.
Figure 9. Caspase 1 activity levels in human lung samples. Lung samples were collected from transplant surgery either donor tissue (non-
smokers or smokers) or diseased tissue. Caspase 1 activity in the cytoplasmic fraction of the extracted lung tissue was assessed using a specific assay.
Data represent as individual data with bar indicating mean 6 s.e.mean. * indicates statistically significant difference from non-smoking donor lung
tissue levels (One-way ANOVA with a Dunn’s post test).
doi:10.1371/journal.pone.0024097.g009
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control group (Mann-Whitney test and one-way ANOVA followed
by a Dunn’s post test).
(TIF)
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